Clinical Trials Logo

Clinical Trial Summary

Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be effective in heterogeneous, treatment-resistant tumors such as Glioblastoma. fb-PMT also is actively transported across the blood-brain barrier into the brain. This study is being conducted to determine the dose level for further clinical development of fb-PMT to treat recurrent Glioblastoma.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05226494
Study type Interventional
Source NanoPharmaceuticals LLC
Contact Adam Blanchard
Phone (203) 499-9297
Email adam.blanchard@yale.edu
Status Recruiting
Phase Phase 1
Start date June 23, 2022
Completion date October 1, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05557240 - Neoantigens Phase I Trial in Newly Diagnosed Glioblastoma Patients N/A
Recruiting NCT05474573 - Concurrent Fluorescence and Sonographically Guided Eradication of Contrast-enhancing Gliomas and Metastases N/A
Recruiting NCT05485038 - General Anesthesia Versus Awake Surgery in Resection of Gliomas and Metastases of Motor Areas N/A
Active, not recruiting NCT04547621 - HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM Phase 1/Phase 2
Recruiting NCT05076513 - Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma Early Phase 1
Completed NCT05806619 - Glioma: Biomolecular Aspects
Not yet recruiting NCT04562077 - Role of Surgery in Treatment of Recurrent Brian Glioma:Prognostic Factors and Outcome
Recruiting NCT06038760 - Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
Completed NCT04497142 - Effect of Perampanel on Peritumoral Hyperexcitability in HGG Phase 1/Phase 2
Recruiting NCT05500508 - Oral AMXT 1501 Dicaprate in Combination With IV DFMO Phase 1/Phase 2
Active, not recruiting NCT05656053 - Intraoperative Rapid Diagnosis of Glioma Based on Fusion of Magnetic Resonance and Ultrasound Imaging
Recruiting NCT06196918 - Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients N/A
Recruiting NCT05556486 - Mapping of Tumor Stem Cells in the Resection Marigin During Extirpation of Highly Malignant Gliomas Using GlioStem
Recruiting NCT05406700 - Niraparib In Recurrent IDH 1/2 Gliomas Early Phase 1
Recruiting NCT05773326 - Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG Early Phase 1
Active, not recruiting NCT05063682 - The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients Phase 1
Completed NCT05100602 - Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients
Completed NCT05100173 - Clinical Evaluation of Genetron IDH1 PCR Kit in Glioma Patients
Recruiting NCT05182905 - AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients Early Phase 1
Recruiting NCT06381726 - Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life N/A